Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population  

作　　者：Wei HONG Kai WANG Yi-ping ZHANG Jun-yan KOU Dan HONG Dan SU Wei-min MAO Xin-min YU Fa-jun XIE Xiao-jian WANG 

机构地区：[1]Department of Medical Oncology,Zhejiang Cancer Hospital [2]Zhejiang Key Laboratory of the Diagnosis and Treatment Technology on Thoracic Oncology [3]Department of Respiratory Medicine,the Second Affiliated Hospital,School of Medicine,Zhejiang University [4]Department of Medical Oncology,Hangzhou Cancer Hospital [5]Institute of Immunology,School of Medicine,Zhejiang University

出　　处：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2013年第3期207-215,共9页浙江大学学报（英文版）B辑（生物医学与生物技术）

基　　金：supported by the National Natural Science Foundation of China (No.30900654);the Medical Scientific Research Foundation of Zhejiang Province (Nos.2007B025,2010KYA036,and 2010KYA032);the Science and Technology Department of Zhejiang Province(Nos.2011c23017 and 2012c23081);the Zhejiang Major Science and Technology Special Project (No.2009C13018),China

摘　　要：Objective： The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase （MTHFR） C677T excision repair cross-complementation group 1 （ERCC1） genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer （NSCLC）. Methods： A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regi- mens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 Cl18T were genotyped using the TaqMan methods. Results： The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype （TT or CT） （41.2% versus 19.1%, P=0.01 ）. Median time to progression （TTP） of patients with MTHFR CC genotype was longer than that of patients with variant genotype （7.6 months versus 5.0 months, P=0.003）. No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival. Conclusions： Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.Objective:The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase(MTHFR) C677T excision repair cross-complementation group 1(ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer(NSCLC).Methods:A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens.The polymorphisms of MTHFR C677T,ERCC1 C8092A,and ERCC1 C118T were genotyped using the TaqMan methods.Results:The overall response rate was 28.9%.Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype(TT or CT)(41.2% versus 19.1%,P=0.01).Median time to progression(TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype(7.6 months versus 5.0 months,P=0.003).No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.Conclusions:Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.

关 键 词：Non-small cell lung cancer Single nucleotide polymorphism Methylenetetrahydrofolate reductase GEMCITABINE Excision repair cross-complementation group 1 

分 类 号：R734.2[医药卫生—肿瘤]